Intrahepatic Cholangiocarcinoma Market Size, Epidemiology Forecast, Pipeline Therapies, Treatment and Key Companies by DelveInsight | Incyte Corporation, Roche, Delcath System, Basilea Pharmaceutica

May 04 13:25 2022
Intrahepatic Cholangiocarcinoma Market Size, Epidemiology Forecast, Pipeline Therapies, Treatment and Key Companies by DelveInsight | Incyte Corporation, Roche, Delcath System, Basilea Pharmaceutica
Intrahepatic Cholangiocarcinoma Market

Intrahepatic Cholangiocarcinoma, a primary malignant neoplasm of the liver secondary to hepatocellular carcinoma, arises from the intrahepatic biliary epithelium (lining epithelia and peribiliary glands) and shows a variable cholangiocytic differentiation. The malignant tumor may arise from any portion of the bile duct epithelium, i.e., anywhere from the terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural).


DelveInsight’s ‘ Intrahepatic Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast 2032‘ report deliver an in-depth understanding of the ICCA, historical and forecasted epidemiology as well as the ICCA market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.


Some facts of Intrahepatic Cholangiocarcinoma Market Report:

  • Among the 7MM, the United States accounts for the highest market size of ICCA in comparison with EU5 and Japan.
  • As per DelveInsight analysts, the total incident population of ICCA in the 7MM was estimated to be 10,343 in 2020.
  • Among the European five countries, Germany had the highest incident population of ICCA with 1,122 cases, followed by Italy and the United Kingdom, which had the incident population of 1,113 and 993 respectively in 2020. On the other hand, Spain had the lowest incident population of 117 cases in 2020.
  • The Intrahepatic Cholangiocarcinoma market size in the 7MM was USD 108.07 Million in 2020.
  • In 2020, out of the total incident cases of ICCA in Germany, males contributed to 52% of the cases.
  • Intrahepatic Cholangiocarcinoma is slightly common in males as compared to females.
  • Melphalan/HDS (Delcath systems), Ivosidenib (Agios Pharmaceuticals), Infigratinib (QED Therapeutics), Futibatinib (Taiho Oncology), Bintrafusp alfa (Merck KGaA/GSK), Derazantinib (Basilea Pharmaceutica), Larotrectinib (Loxo Oncology/Bayer), Copanlisib (Bayer), E7090 (Eisai), Regorafenib (Bayer), and Futibatinib (Taiho Oncology) are expected to enter in the market during the forecasted period (2021–2030).


Request for sample pages of the report:


Intrahepatic Cholangiocarcinoma Companies involved:

  • Incyte Corporation
  • Roche
  • Delcath Systems
  • Basilea Pharmaceutica
  • Agios Pharmaceuticals
  • Bayer
  • Loxo Oncology/Bayer
  • QED Therapeutics
  • Janssen Pharmaceutical
  • Taiho Oncology
  • RedHill Biopharma
  • GlaxoSmithKline
  • Merck/GlaxoSmithKline
  • Eisai
  • Taiho Pharmaceutical/Servier
  • Bayer
  • Sorrento Therapeutics/Yuhan Corporation
  • Hutchison Medipharma
  • Jiangsu HengRui Medicine
  • AstraZeneca
  • Eli Lilly
  • Servier Laboratories
  • Genoscience Pharma
  • Forma Therapeutics
  • Array BioPharma
  • And Many Others



Request for sample pages of the report:


Intrahepatic Cholangiocarcinoma Market Outlook

Intrahepatic cholangiocarcinoma (ICCA) is the type of CCA that forms in the bile ducts inside the liver. The commonly available modalities for the treatment of ICCA include surgery and radiation therapies for curative intent and systemic therapies, including chemotherapy and chemoradiotherapy, for the surgery of ineligible patients.

Surgical resection is the mainstay for the treatment of ICCA. The main goal of the surgery is the hepatic resection with negative margins. Since this type of cancer occurs in the bile ducts inside the liver, surgery may include removing the section or wedge of the liver, and its extent depends on tumor size and location.

Locoregional therapies such as RFA, TACE, DEB-TACE or TACE drug-eluting microspheres, and TARE with yttrium-90 microspheres have shown to be effective in a retrospective analysis of patients with ICCA. Besides these, radiation therapy is also a locoregional treatment option for unresectable ICCA. Fewer patients with ICCA are also given ablation. Although all guidelines recommend radiofrequency ablation (RFA) as a standard treatment for patients with small, early-stage HCC not suitable for surgical therapies, in some cases, patients with ICCA are also treated with RFA.


Intrahepatic Cholangiocarcinoma Therapies:

  • Pemazyre (Pemigatinib)
  • Rozlytrek (Entrectinib)
  • Melphalan/HDS
  • Derazantinib
  • Ivosidenib
  • Regorafenib
  • Larotrectinib
  • Infigratinib
  • Balversa (Erdafitinib)
  • Futibatinib (TAS-120)
  • Opaganib (ABC294640; Yeliva)
  • Niraparib (Zejula)
  • Bintrafusp alfa (GSK4045154; M7824)
  • E7090
  • Lonsurf (Trifluridine and Tipiracil Hydrochloride/TAS-102)
  • Copanlisib (BAY 80-6946)
  • STI-3031 (IMC-001)
  • HMPL-453
  • Famitinib
  • Durvalumab
  • Abemaciclib
  • Nal-IRI with 5-fluorouracil and/or Leucovorin
  • GNS561
  • Olutasidenib (FT-2102)
  • Gemcitabine, Cisplatin, and MEK162
  • And Many Others


Request for sample pages of the report:


Table of contents:

  1. Key Insight
  2. Executive Summary of Intrahepatic Cholangiocarcinoma (ICCA)
  3. Intrahepatic Cholangiocarcinoma (ICCA) Market Overview at a Glance
  4. Disease Background and Overview: Intrahepatic Cholangiocarcinoma (ICCA)
  5. Case Reports
  6. Intrahepatic Cholangiocarcinoma (ICCA) Epidemiology and Patient Population
  7. United States Epidemiology
  8. EU5 Epidemiology
  9. Japan Epidemiology
  10. Current Intrahepatic Cholangiocarcinoma (ICCA) Treatment and Medical Practices
  11. Unmet needs
  12. Intrahepatic Cholangiocarcinoma (ICCA) Marketed Drugs
  13. Intrahepatic Cholangiocarcinoma (ICCA) Emerging Drugs
  14. Intrahepatic Cholangiocarcinoma (ICCA) 7MM Market Analysis
  15. United States
  16. EU-5 countries: Market Outlook
  17. Japan Market Outlook
  18. Intrahepatic Cholangiocarcinoma (ICCA) Market Drivers
  19. Intrahepatic Cholangiocarcinoma (ICCA) Market Barriers
  20. SWOT Analysis
  21. Reimbursement and market access
  22. Appendix
  23. DelveInsight Capabilities
  24. Disclaimer


About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States